We are studying a combination of bicalutamide and abemaciclib for patients with AR positive triple-negative breast cancer. The goal is to see if this treatment helps control the disease and to evaluate its safety.
Health conditions and diseases that the clinical trial is designed to study and treat.
This condition refers to a type of breast cancer that is locally advanced or has spread to other parts of the body, characterized by being androgen receptor positive and triple negative, meaning it does not have estrogen or progesterone receptors and does not overexpress HER2. It is progressive after at least one prior treatment regimen.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.